Suppr超能文献

用于预防和治疗心力衰竭的血管紧张素转换酶抑制剂:为何“使用不足”?

ACE inhibitors for the prevention and treatment of heart failure: why are they 'under-used'?

作者信息

Cleland J G

机构信息

MRC Clinical Research Initiative in Heart Failure, University of Glasgow and Western Infirmary, UK.

出版信息

J Hum Hypertens. 1995 Jun;9(6):435-42.

PMID:7473524
Abstract

Currently there is concern that ACE inhibitors are not being utilised to their maximum potential for the prevention or treatment of heart failure. Underutilisation of ACE inhibitors has been attributed to a lack of appropriate medical education of physicians. However, an alternative explanation is that the trials have failed to answer important questions about how ACE inhibitors should be used in heart failure and that physician prescribing is appropriate to the current state of knowledge. The lack of evidence of benefit in patients with heart failure over the age of 75 years and of any substantial controlled trial in patients with apparent heart failure and well-preserved left ventricular systolic function, a common finding in elderly patients, may be common reasons why ACE inhibitors appear to be prescribed infrequently for heart failure.

摘要

目前人们担心,在预防或治疗心力衰竭方面,血管紧张素转换酶(ACE)抑制剂未得到充分利用。ACE抑制剂的使用不足被认为是由于医生缺乏适当的医学教育。然而,另一种解释是,试验未能回答有关ACE抑制剂在心力衰竭中应如何使用的重要问题,而且医生的处方是符合当前知识水平的。在75岁以上心力衰竭患者中缺乏获益证据,以及在明显心力衰竭且左心室收缩功能保存良好(这在老年患者中很常见)的患者中缺乏任何大规模对照试验,可能是ACE抑制剂在心力衰竭中处方率似乎较低的常见原因。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验